StockNews.AI
INCY
StockNews.AI
210 days

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

1. Incyte will announce Q4 and YE 2024 results on February 10, 2025. 2. The press release will be available at 7:00 a.m. ET on the same date. 3. A live conference call follows the release at 8:00 a.m. ET.

Earnings
+0.71%Current Return
VS
+1.61%S&P 500
$71.9301/21 08:33 AM EDTEvent Start
$72.4401/22 03:21 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results may not significantly alter current perception, similar to past events.

How important is it?

Earnings reports generally impact stock movements, though broader market factors may play a bigger role.

Why Short Term?

Expectations for Q4 results will short-term influence trading activity.

Related Companies

INCY
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2024 Press Release: February 10, 2025 at 7:00 a.m. ET • Q4 & YE 2024 Conference Call: February 10, 2025 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13751174 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13751174. The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Related News